Methotrexate: Improving safety profile

Australasian Journal of Dermatology

Volumn 47, Issue 3, 2006, Pages 178-181

  Grills, Claire ^a   Burge, Susan ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Audit; Folic acid; Haematological monitoring; Information sheet; Liver function test; Monitoring; Procollagen peptide III; Psoriasis; Renal function test

Indexed keywords

METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ARTICLE; BLOOD TOXICITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PSORIASIS;

BLOOD CHEMICAL ANALYSIS; COLLAGEN TYPE III; DERMATOLOGIC AGENTS; DRUG MONITORING; DRUG UTILIZATION REVIEW; ELECTROLYTES; FOLIC ACID; GREAT BRITAIN; HUMANS; LIVER FUNCTION TESTS; METHOTREXATE; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; UREA;

EID: 33745751256     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2006.00267.x     Document Type: Article

References (10)

1. Methotrexate Patient Safety Alert. National Patient Safety Authority. July 2004. Available from URL: http:// www.npsa.nhs.uk (Accessed 12 Apr 2005.)
2. Mathew T, Isaacs D, Lander C, Shenfireld G, Wainwright D, Wing L. Methotrexate misadventures - a need for care and counselling. Aust. Adv. Drug React. Bull. 1999; 18: 4.
3. Tanya N. Concerns over medication errors in Australian hospitals. The World Today. 9 May 2005. Available from URL: http://www.abc.net.au (Accessed 12 Sep 2005.)
4. Scottish Dermatological Society. Methotrexate. Clinical Audit Standards. 2002. Available from URL: http://www.bad.org.uk (Accessed 17 Nov 2004.)
5. Chalmers RJG, Smith A, Burrows P, Little R, Horan M, Hextall JM, Smith CH, Klaber M, Rogers S. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br. J. Dermatol. 2005; 152: 444-54.
6. Maurice PDL, Green CA, Tatnall F, Schofield JK, Stott DJ. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br. J. Dermatol. 2005; 152: 451-8.
7. Roenigk HH Jr, Auerbach R, Maibach H. Methotrexate hi psoriasis: consensus conference. J. Am. Acad. Dermatol. 1998; 38: 478-85.
8. Van Dooren-Grebe RJ, Mulder J, De Boo T, Van de Kerkhof PCM. Methotrexate revisited: effects of long-term treatment in psoriasis. Br. J. Dermatol. 1994; 130: 130-2.
9. Ortiz Z, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). The Cochrane Library. 2000; 2: CD000951.
10. British Association of Dermatologists. Methotrexate. Clinical Guidelines. 2005. Available from URL: http://www.bad.org.uk (Accessed 15 Apr 2005.)